InflaRx N.V.

NASDAQ:IFRX

Biotechnology

Healthcare
$1.11 -0.82%

-$0.02 today

Market cap
$163.58M
Beta
2.44
P/E (TTM)
-2.7
EPS (TTM)
-$0.59
52W Low $0.74High $2.95

Volume 3.05M

Average 1.80M

IFRX Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

InflaRx N.V.NASDAQ: IFRX

Change in Working Capital · Q1 FY2026 · quarter ended Mar 2026

Change in working capital dips below year-ago levels

Q1 FY2026 change in working capital of €1.46M (cash outflow) fell 72.1% year over year, behind the +450.5% change in trailing-twelve-month change in working capital.

Context

  • Change in working capital amounted to 15902.8% of revenue in FY2025, up 14528.5 pp from a year earlier.
  • Change in working capital increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from -72.1% toward the trailing-twelve-month pace of +450.5%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
-€1.46M-121.5% QoQ
Last fiscal yearDec 2025
€4.66M+304.7% YoY
LTMMar 2026
€8.45M+450.5% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-72.1%——
1 year+304.7%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

EUR · from the cash flow

Latest · FY2025
4.66M EUR
Year-over-year change
+304.7%
4-year CAGR
+32.0%

Change in Working Capital vs competitors

How IFRX compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +450.5% is the 3rd highest of 8, against a peer median of +103.7%.
  • Change in working capital amounts to 28812.5% of revenue for IFRX, versus a peer median of 539.6%.
IFRX Competitors
Change in Working Capital for IFRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
STROSutro Biopharma, Inc.LTM Mar 2026$58.2M USD-455.5%—58.4%
IMAImageneBio IncLTM Mar 2026$21.14M USD+968.3%+8.2%—
IFRXInflaRx N.V.LTM Mar 2026€8.45M EUR+450.5%—28812.5%
ATYRaTyr Pharma, Inc.LTM Mar 2026$5.86M USD+748.8%—3083.7%
ARTVArtiva Biotherapeutics, Inc.LTM Mar 2026$4.39M USD-464.7%-52.1%—
CNTXContext Therapeutics Inc.LTM Mar 2026$3.86M USD+216.5%——
STTKShattuck Labs, Inc.LTM Mar 2026$1.73M USD-162.8%-44.0%172.9%
CNTBConnect Biopharma Holdings LimitedFY2025$580K USD+103.7%-56.7%906.3%
KLRSKalaris Therapeutics IncLTM Mar 2026$53K USD—+0.3%—
Peer median (excluding IFRX) —+103.7%-44.0%539.6%

Competitors are the stored peer set for IFRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

EUR
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(45.63M)(29.48M)(42.67M)(46.06M)(43.83M)
Depreciation & Amortization669.43K596.6K567.78K485.11K402.93K
Deferred Income Tax1.16M0000
Stock-Based Compensation4.33M6.04M3.41M4.07M0
Change in Working Capital1.54M(9.77M)1M(2.28M)4.66M
Accounts Receivables00002.12M
Inventory00(11.37M)4.47M6.63M
Accounts Payables316.11K(3.52M)00(5.76M)
Other Working Capital1.22M(6.25M)12.37M(6.75M)1.68M
Other Non-Cash Items(2M)(1.13M)(131.29K)(4.76M)4.84M
Operating Cash Flow(39.94M)(33.74M)(37.81M)(48.56M)(33.92M)
Capital Expenditures(37.78K)(162.39K)(81.1K)(46.87K)(111.13K)
Acquisitions (Net)37.78K(19.52M)000
Purchases of Investments(97.52M)(64.47M)(104.05M)(35.34M)(44.28M)
Sales of Investments71.6M84M86.44M87.75M47.5M
Other Investing Activities(37.78K)19.52M01(3)
Investing Cash Flow(25.95M)19.36M(17.7M)52.36M3.11M
Debt Repayment(360.64K)(364.43K)(373.98K)(388.11K)(357.58K)
Common Stock Issued65.14M2.35M56.48M1.1M32.35M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities(3.2M)(47.74K)(3.12M)(323.73K)14.11K
Financing Cash Flow61.58M1.94M52.99M386.45K32M
Effect of Forex Changes4.59M2.46M(974.1K)1.41M(1.37M)
Net Change in Cash281.31K(9.98M)(3.5M)5.61M(179.66K)
Free Cash Flow(39.97M)(33.91M)(37.89M)(48.6M)(34.03M)

InflaRx N.V.

NASDAQ:IFRX

Intrinsic Alpha fair value

Locked

Current Price

$1.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.